Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis | Zendy

Gilbert H. Daniels | Zendy; Anton Vladić | Zendy; Vesna Brinar | Zendy; И. А. Завалишин | Zendy; WILLIAM A. VALENTE | Zendy; Pedro Oyuela | Zendy; Jeffrey Palmer | Zendy; David Margolin | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Alemtuzumab-Related Thyroid Dysfunction in a Phase 2 Trial of Patients With Relapsing-Remitting Multiple Sclerosis

Author(s) -

Gilbert H. Daniels,

Anton Vladić,

Vesna Brinar,

И. А. Завалишин,

WILLIAM A. VALENTE,

Pedro Oyuela,

Jeffrey Palmer,

David Margolin

Publication year - 2013

Publication title -

the journal of clinical endocrinology and metabolism

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.206

H-Index - 353

eISSN - 1945-7197

pISSN - 0021-972X

DOI - 10.1210/jc.2013-2201

Subject(s) - medicine , alemtuzumab , thyroid , multiple sclerosis , euthyroid , interferon beta 1a , thyroid function , gastroenterology , anti thyroid autoantibodies , thyroid peroxidase , thyroiditis , population , pediatrics , immunology , antibody , autoantibody , transplantation , interferon beta , environmental health

Alemtuzumab, an anti-CD52 monoclonal antibody, increased the risk of thyroid dysfunction in CAMMS223, a phase 2 trial in relapsing-remitting multiple sclerosis.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research